Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mead Johnson preps for IPO

This article was originally published in The Tan Sheet

Executive Summary

An initial public offering for Bristol-Myers Squibb's subsidiary, Mead Johnson Nutrition, will initialize the week of Feb. 9 at a price of $21 to $24 per share of Class A common stock, which will trade under the ticker symbol MJN. Net proceeds are estimated at $530 million to $610 million, depending on whether underwriters exercise over-allotment actions, according to a prospectus filed Jan. 28. Based on the implied IPO price, the marketer of Enfamil pediatric formula likely will have 200 million shares and a market value of $4.5 billion, according to Deutsche Bank analyst Barbara Ryan. BMS intends to maintain an 80 percent to 90 percent ownership stake in Mead Johnson, which generated $2.88 billion in net sales in 2008. In April 2008, BMS announced plans to spin off the nutritionals business in an IPO rather than sell it (1"The Tan Sheet," April 28, 2008, p. 14)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS102590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel